Endometrial safety of ospemifene: Results of the phase 2/3 clinical development program

Menopause

Volumn 22, Issue 1, 2015, Pages 36-43

  Constantine, Ginger D ^a   Goldstein, Steven R ^b   Archer, David F ^c  

^a EndoRheum Consultants   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c The Jones Institute for Reproductive Medicine   (United States)

Author keywords

Endometrial safety; Endometrium; Estrogen receptor agonist antagonist; Lubricant; Ospemifene; Vaginal examination; Vulvar and vaginal atrophy

Indexed keywords

OSPEMIFENE; PLACEBO; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CYSTOCELE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ENDOMETRIAL THICKNESS; ENDOMETRIUM; ENDOMETRIUM BIOPSY; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; FEMALE; FOLLOW UP; GYNECOLOGICAL EXAMINATION; HISTOPATHOLOGY; HOT FLUSH; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MIDDLE AGED; MORNING DOSAGE; MUSCLE SPASM; OUTCOME ASSESSMENT; PELVIC ORGAN PROLAPSE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPOTTING; TRANSVAGINAL ECHOGRAPHY; VAGINA ATROPHY; VAGINA BLEEDING; VAGINA DISCHARGE; VULVA DISEASE; VULVAR ATROPHY; ANALOGS AND DERIVATIVES; ATROPHY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; DYSPAREUNIA; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; VAGINA; VAGINAL DISEASES; VERY ELDERLY; VULVA;

ADULT; AGED; AGED, 80 AND OVER; ATROPHY; DOUBLE-BLIND METHOD; DYSPAREUNIA; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; MIDDLE AGED; PLACEBOS; POSTMENOPAUSE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; VAGINA; VAGINAL DISEASES; VULVA;

EID: 84920278571     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0000000000000275     Document Type: Article

References (25)

1. The North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013;20:888-902.
2. Riggs BL, Hartmann LC. Selective estrogen-receptor modulatorsV mechanisms of action and application to clinical practice. N Engl J Med 2003;348:618-629.
3. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-2197.
4. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388.
5. Goldstein SR, Neven P, Cummings S, et al. Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) trial: 5-year gynecological outcomes. Menopause 2011;18:17-22.
6. Qu Q, Zheng H, Dahllund J, et al. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology 2000;141:809-820.
7. Voipio SK, Komi J, Kangas L, Halonen K, DeGregorio MW, Erkkola RU. Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women. Maturitas 2002;43:207-214.
8. Unkila M, Kari S, Yatkin E, Lammintausta R. Vaginal effects of ospemifene in the ovariectomized rat preclinical model of menopause. J Steroid Biochem Mol Biol 2013;138:107-115.
9. Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975;293:1167-1170.
10. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1996;275:370-375.
11. Pickar JH, Yeh I, Wheeler JE, CunnaneMF, Speroff L. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;76:25-31.
12. Labrie F, Cusan L, Gomez JL, et al. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. Menopause 2009;16:30-36.
13. Simon J, Nachtigall L, Ulrich LG, Eugster-Hausmann M, Gut R. Endometrial safety of ultra-low-dose estradiol vaginal tablets. Obstet Gynecol 2010;116:876-883.
14. Bachmann G, Bouchard C, Hoppe D, et al. Efficacy and safety of lowdose regimens of conjugated estrogens cream administered vaginally. Menopause 2009;16:719-727.
15. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Estrogen and Estrogen/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy SymptomsVRecommendations for Clinical Evaluation. Rockville, MD: Center for Drug Evaluation and Research; 2003.
16. Bachmann GA, Komi JO; The Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause 2010;17:480-486.
17. Portman DJ, Bachmann GA, Simon JA; The Ospemifene Study Group. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause 2013;20:623-630.
18. Simon JA, Lin VH, Radovich C, Bachmann GA; The Ospemifene Study Group. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause 2013;20:418-427.
19. Portman D, Palacios S, Nappi RE, Mueck AO. Ospemifene, a nonoestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial. Maturitas 2014; 78:91-98.
20. Goldstein SR, Bachmann GA, Koninckx PR, et al. Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric 2014;17:173-182.
21. Mutter GL, Ferenczy A. Anatomy and histology of the uterine corpus. In: Kurman RJ, ed. Blaustein's Pathology of the Female Genital Tract. 5th ed. New York, NY: Springer-Verlag; 2002:380-420.
22. Dreisler E, Stampe Sorensen S, Ibsen PH, Lose G. Prevalence of endometrial polyps and abnormal uterine bleeding in a Danish population aged 20-74 years. Ultrasound Obstet Gynecol 2009;33:102-108.
23. Pinkerton JV, Goldstein SR. Endometrial safety: a key hurdle for selective estrogen receptor modulators in development. Menopause 2010;17:642-653.
24. McGonigle KF, Shaw SL, Vasilev SA, Odom-Maryon T, Roy S, Simpson JF. Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atrophy. Am J Obstet Gynecol 1998;178:1145-1150.
25. Goldstein SR, ScheeleWH, Rajagopalan SK,Wilkie JL,Walsh BW, Parsons AK. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstet Gynecol 2000;95:95-103.